Clinical Trial Update: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for FOLFSIM Plus Toripalimab in advanced/metastatic neuroendocrine carcinoma of the bladder across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma of the Bladder

Drugs mentioned

• FOLFSIM
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking University | Conditions: Neuroendocrine Carcinoma of the Bladder | Phase 2, Phase 3 | Status: UNKNOWN